Literature DB >> 23738575

Coarse grained molecular dynamics of engineered macromolecules for the inhibition of oxidized low-density lipoprotein uptake by macrophage scavenger receptors.

Michael D Tomasini1, Kyle Zablocki, Latrisha K Petersen, Prabhas V Moghe, M Silvina Tomassone.   

Abstract

Atherosclerosis is a condition resulting from the accumulation of oxidized low-density lipoproteins (oxLDLs) in arterial walls. Previously developed macromolecules consisting of alkyl chains and polyethylene glycol (PEG) on a mucic acid backbone, termed nanolipoblockers (NLBs) are hypothesized to mitigate the uptake of oxLDL by macrophage scavenger receptors. In this work, we developed a coarse grained model to characterize the interactions between NLBs with a segment of human scavenger receptor A (SR-A), a key receptor domain that regulates cholesterol uptake and foam cell conversion of macrophages, and studied NLB ability to block oxLDL uptake in PBMC macrophages. We focused on four different NLB configurations with variable molecular charge, charge location, and degree of NLB micellization. Kinetic studies showed that three of the four NLBs form micelles within 300 ns and of sizes comparable to literature results. In the presence of SR-A, micelle-forming NLBs interacted with the receptor primarily in an aggregated state rather than as single unimers. The model showed that incorporation of an anionic charge near the NLB mucic acid head resulted in enhanced interaction with the proposed binding pocket of SR-A compared to uncharged NLBs. By contrast, NLBs with an anionic charge located at the PEG tail showed no interaction increase as NLB aggregates were predominately observed to interact away from the oxLDL binding site. Additionally, using two different methods to assess the number of contacts that each NLB type formed with SR-A, we found that the rank order of contacts coincided with our experimental flow cytometry results evaluating the ability of the different NLBs to block the uptake of oxLDL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23738575     DOI: 10.1021/bm301764x

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  4 in total

Review 1.  Multiscale technologies for treatment of ischemic cardiomyopathy.

Authors:  Morteza Mahmoudi; Mikyung Yu; Vahid Serpooshan; Joseph C Wu; Robert Langer; Richard T Lee; Jeffrey M Karp; Omid C Farokhzad
Journal:  Nat Nanotechnol       Date:  2017-09-06       Impact factor: 39.213

2.  Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo.

Authors:  Daniel R Lewis; Latrisha K Petersen; Adam W York; Kyle R Zablocki; Laurie B Joseph; Vladyslav Kholodovych; Robert K Prud'homme; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

3.  Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques.

Authors:  Daniel R Lewis; Latrisha K Petersen; Adam W York; Sonali Ahuja; Hoonbyung Chae; Laurie B Joseph; Saum Rahimi; Kathryn E Uhrich; Paul B Haser; Prabhas V Moghe
Journal:  Cardiovasc Res       Date:  2015-10-14       Impact factor: 13.081

4.  Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs.

Authors:  Olga B Garbuzenko; Jennifer Winkler; M Silvina Tomassone; Tamara Minko
Journal:  Langmuir       Date:  2014-10-27       Impact factor: 3.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.